CN101203270A - 具有体重再分配性能的物质 - Google Patents
具有体重再分配性能的物质 Download PDFInfo
- Publication number
- CN101203270A CN101203270A CNA2006800196260A CN200680019626A CN101203270A CN 101203270 A CN101203270 A CN 101203270A CN A2006800196260 A CNA2006800196260 A CN A2006800196260A CN 200680019626 A CN200680019626 A CN 200680019626A CN 101203270 A CN101203270 A CN 101203270A
- Authority
- CN
- China
- Prior art keywords
- fat
- mass
- effective dose
- body weight
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 87
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 239000000651 prodrug Substances 0.000 claims abstract description 25
- 229940002612 prodrug Drugs 0.000 claims abstract description 25
- 238000009826 distribution Methods 0.000 claims abstract description 13
- 230000037396 body weight Effects 0.000 claims description 77
- 235000013824 polyphenols Nutrition 0.000 claims description 73
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 72
- 235000013379 molasses Nutrition 0.000 claims description 63
- 244000269722 Thea sinensis Species 0.000 claims description 57
- 239000000284 extract Substances 0.000 claims description 54
- 244000299461 Theobroma cacao Species 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 45
- 235000019219 chocolate Nutrition 0.000 claims description 38
- 230000008859 change Effects 0.000 claims description 31
- 235000009569 green tea Nutrition 0.000 claims description 25
- 241001597008 Nomeidae Species 0.000 claims description 24
- 235000013616 tea Nutrition 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 21
- 235000009392 Vitis Nutrition 0.000 claims description 20
- 241000219095 Vitis Species 0.000 claims description 20
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229930003935 flavonoid Natural products 0.000 claims description 12
- 150000002215 flavonoids Chemical class 0.000 claims description 12
- 235000017173 flavonoids Nutrition 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 235000013599 spices Nutrition 0.000 claims description 12
- 230000003064 anti-oxidating effect Effects 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 11
- 235000014101 wine Nutrition 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 239000002417 nutraceutical Substances 0.000 claims description 9
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- 235000005822 corn Nutrition 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 235000013405 beer Nutrition 0.000 claims description 3
- 235000016213 coffee Nutrition 0.000 claims description 3
- 235000013353 coffee beverage Nutrition 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 229940119429 cocoa extract Drugs 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 90
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 55
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 55
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 55
- 239000000523 sample Substances 0.000 description 51
- 239000000843 powder Substances 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 230000003647 oxidation Effects 0.000 description 19
- 238000007254 oxidation reaction Methods 0.000 description 19
- 210000000582 semen Anatomy 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 235000013305 food Nutrition 0.000 description 18
- 230000036541 health Effects 0.000 description 18
- 210000000577 adipose tissue Anatomy 0.000 description 17
- 150000002989 phenols Chemical class 0.000 description 17
- 235000006468 Thea sinensis Nutrition 0.000 description 15
- 235000005487 catechin Nutrition 0.000 description 15
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 15
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 14
- 229950001002 cianidanol Drugs 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 13
- 230000003078 antioxidant effect Effects 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 235000020824 obesity Nutrition 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 235000002357 Ribes grossularia Nutrition 0.000 description 12
- 235000020279 black tea Nutrition 0.000 description 12
- 102000005862 Angiotensin II Human genes 0.000 description 11
- 101800000733 Angiotensin-2 Proteins 0.000 description 11
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 11
- 244000171263 Ribes grossularia Species 0.000 description 11
- 229950006323 angiotensin ii Drugs 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 10
- 239000011707 mineral Substances 0.000 description 10
- 235000010755 mineral Nutrition 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 206010033307 Overweight Diseases 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 description 7
- 235000010208 anthocyanin Nutrition 0.000 description 7
- 229930002877 anthocyanin Natural products 0.000 description 7
- 239000004410 anthocyanin Substances 0.000 description 7
- 150000004636 anthocyanins Chemical class 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 7
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 208000020442 loss of weight Diseases 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- 102000004366 Glucosidases Human genes 0.000 description 5
- 108010056771 Glucosidases Proteins 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 5
- 235000019418 amylase Nutrition 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000005693 branched-chain amino acids Chemical class 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 230000037219 healthy weight Effects 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920000855 Fucoidan Polymers 0.000 description 4
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 244000082988 Secale cereale Species 0.000 description 4
- 235000007238 Secale cereale Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 235000019221 dark chocolate Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000020688 green tea extract Nutrition 0.000 description 4
- 229940094952 green tea extract Drugs 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 229940089491 hydroxycitric acid Drugs 0.000 description 4
- 238000003801 milling Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 235000019220 whole milk chocolate Nutrition 0.000 description 4
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 3
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 3
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 240000004580 Magnolia hypoleuca Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 229940024171 alpha-amylase Drugs 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 235000021028 berry Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000007242 delphinidin Nutrition 0.000 description 3
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 150000007946 flavonol Chemical class 0.000 description 3
- 235000011957 flavonols Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000020333 oolong tea Nutrition 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 238000004260 weight control Methods 0.000 description 3
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 244000080767 Areca catechu Species 0.000 description 2
- 235000006226 Areca catechu Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000007199 Panicum miliaceum Nutrition 0.000 description 2
- 240000008114 Panicum miliaceum Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000007230 Sorghum bicolor Nutrition 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 235000021407 appetite control Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000021038 drupes Nutrition 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- -1 potassium dihydrogen phosphate potassium sulfate potassium citrate Chemical compound 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229940069575 rompun Drugs 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GAKJJSAXUFZQTL-UHFFFAOYSA-N 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)S1 GAKJJSAXUFZQTL-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000532370 Atla Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001091440 Grossulariaceae Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218394 Magnolia liliiflora Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 206010026865 Mass Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- 241000029523 Procapra gutturosa Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 241000219161 Theobroma Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000019581 fat taste sensations Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000020656 green tea supplement Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- GTZCVFVGUGFEME-HNQUOIGGSA-N trans-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C/C(O)=O GTZCVFVGUGFEME-HNQUOIGGSA-N 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
粉末 | 酚类含量(毫克儿茶素等同物/克) | 抗氧化剂含量(毫克没食子酸等同物/克) |
糖蜜粉末 | 254 | 32.2 |
Hansen’s HW 65-10葡萄提取物 | 775 | 144 |
Vinlife葡萄籽提取物 | 533 | 105 |
粉末 | 比活性(没食子酸等同物/儿茶素等同物) |
糖蜜粉末 | 0.127 |
Hansen’s HW 65-10葡萄提取物 | 0.188 |
VinlifeTM葡萄籽提取物 | 0.197 |
对照巧克力 | 强化的巧克力 | ||
样品(列,位置) | 抗氧化能力(毫克儿茶素等同物/克) | 样品(列,位置) | 抗氧化能力(毫克儿茶素等同物/克) |
1,12,13,44,25,36,4 | 1.6381.5781.5721.6341.5471.557 | 1,21,42,12,33,44,14,35,25,46,16,3 | 1.8321.8572.0221.8591.9241.9141.9371.9711.9362.0161.900 |
样品 | 总抗氧化潜力(CE=儿茶素等同物) | |
(毫克CE/毫升) | (毫克CE/克干物质) | |
初榨果汁 | 0.75 | 3.40 |
末道果汁 | 0.12 | 8.76 |
提取自澄清果汁的糖浆 | 2.89 | 3.43 |
糖蜜 | 23.58 | 30.00 |
低醇糖 | - | 2.34 |
滤液 | 0.44 | 3.64 |
甘蔗梢 | 0.44 | 13.54 |
泡沫 | 0.23 | 3.75 |
碾磨浆 | - | 3.17 |
粗糖 | 0.44 | - |
样品 | 多酚(毫克儿茶素等同物/克) | 抗氧化剂(微摩尔/克) |
黑巧克力 | 23.9 | NT |
牛奶巧克力 | 7.25 | 18.3 |
可可液 | 41.8 | 110 |
葡萄籽粉末 | 301.5 | 1146 |
葡萄皮提取物 | 54.5 | 181 |
混合浆果点心 | 12.3 | 9.33 |
混合果汁 | 3.35 | NT |
碾磨浆 | 14.7 | 26.8 |
糖蜜 | 17.87 | 32.58 |
粗糖 | 0.25 | 0.44 |
成分 | 量 |
细白砂糖 | 200千克 |
全脂奶粉 | 70千克 |
可可液(Ivory Coast) | 175千克 |
除臭可可油 | 50千克 |
大豆卵磷脂-(先加一半,在完成巧克力精炼周期前30-60分钟添加一半) | 2.5千克 |
PGPR-(先加一半,1千克,并在添加香料之后添加其余部分(以降低粘度)) | 2.0千克 |
天然香草香料-(在完成巧克力精炼周期之前30分钟添加) | 2.0千克 |
样品 | 样品质量(毫克) | 提取物质量(毫克) | 收率(%) |
糖蜜粉末 | 49.8 | 34.3 | 69 |
绿茶 | 48.5 | 16.3 | 34 |
样品号 | ORAC值(微摩尔TE/克样品) |
糖蜜粉末 | 4395±229 |
绿茶 | 1793±93.5 |
样品号 | ORAC值(微摩尔TE/克样品) |
糖蜜粉末 | 5020±375 |
绿茶 | 1467±90 |
样品 | 浓度(微克/毫升) | %抑制 | IC50 |
糖蜜粉末 | 600 | 88.9±0.7 | 194微克/毫升 |
300 | 65.7±0.1 | ||
150 | 38.4±0.5 | ||
75 | 12.9±0.9 | ||
37.5 | 1.5±0.2 | ||
18.7 | -3.8±0.5 | ||
岩藻依聚糖 | 37.5 | 97.4±5.9 | 14微克/毫升 |
18.8 | 73.5±7.5 | ||
9.4 | 19.3±2.7 | ||
4.7 | 5.7±3.1 |
样品 | 浓度(微克/毫升) | %抑制 | IC50 |
样品1 | 1200 | 9.5±1.7 | - |
600 | -3.6±0.9 | ||
300 | -22.6±1.6 | ||
150 | -30.4±1.6 | ||
阿卡波糖 | 1000 | 95.2±30.1 | 147微克/毫升 |
500 | 80.8±1 0.2 | ||
250 | 61.5±10.3 | ||
125 | 46.4±9.1 |
成分 | %组成 |
蔗糖酪蛋白大豆油可可油酥油(乳脂)金枪鱼油橄榄油亚麻油纤维素淀粉糊精化淀粉 | 10.9320.001.862.515.310.204.230.915.0031.513.2 |
dI蛋氨酸AIN_93_G_痕量矿物质石灰(细碳酸钙)盐(细氯化钠)磷酸二氢钾硫酸钾柠檬酸钾AIN_93_G_维生素氯化胆碱50%w/w | 0.300.141.310.260.690.160.251.000.25 |
参数 | ACE+/+ | ACE-/- |
甘油三酯(毫摩尔/升,n=7) | 0.85±0.26 | 0.47±0.06 |
胆固醇(毫摩尔/升,n=7) | 1.68±0.14 | 1.97±0.11 |
葡萄糖(毫摩尔/升,n=7) | 14.31±1.72 | 10.81±0.87 |
血细胞比容(%,n=5) | 40.5±0.9 | 27.5±1.1*** |
Claims (42)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005902927 | 2005-06-03 | ||
AU2005902927A AU2005902927A0 (en) | 2005-06-03 | Substances having body mass redistribution properties | |
PCT/AU2006/000769 WO2006128259A1 (en) | 2005-06-03 | 2006-06-05 | Substances having body mass redistribution properties |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101203270A true CN101203270A (zh) | 2008-06-18 |
CN101203270B CN101203270B (zh) | 2014-07-02 |
Family
ID=37481164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680019626.0A Active CN101203270B (zh) | 2005-06-03 | 2006-06-05 | 具有体重再分配性能的物质 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8021697B2 (zh) |
EP (2) | EP1885453A4 (zh) |
JP (1) | JP5775656B2 (zh) |
CN (1) | CN101203270B (zh) |
AU (1) | AU2006254652B2 (zh) |
BR (1) | BRPI0613305B1 (zh) |
CA (1) | CA2608865C (zh) |
ES (1) | ES2457595T3 (zh) |
HK (1) | HK1170971A1 (zh) |
MX (1) | MX2007014586A (zh) |
WO (1) | WO2006128259A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103561585A (zh) * | 2011-02-08 | 2014-02-05 | 视界科技有限公司 | 糖提取物 |
CN105722520A (zh) * | 2013-08-16 | 2016-06-29 | 产品制造商(澳大利亚)有限公司 | 甘蔗衍生提取物及治疗方法 |
CN107922458A (zh) * | 2015-07-01 | 2018-04-17 | 三得利控股株式会社 | 含有氨基酸及环状二肽的组合物 |
CN112384074A (zh) * | 2018-05-11 | 2021-02-19 | 产品制造商(澳大利亚)有限公司 | 用于动物饲料的甘蔗提取物 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503417A (ja) | 2006-09-19 | 2010-02-04 | ホリズン サイエンス ピーティーワイ リミテッド | サトウキビに由来する抽出物、およびこれらの製造方法 |
GB0719542D0 (en) | 2007-10-08 | 2007-11-14 | Barry Callebaut Ag | Use of cocoa extract |
GB0719544D0 (en) | 2007-10-08 | 2007-11-14 | Barry Callebaut Ag | Cocoa extract and use thereof |
GB0719545D0 (en) * | 2007-10-08 | 2007-11-14 | Barry Callebaut Ag | Novel use of cocoa extract |
US8263069B2 (en) | 2008-12-31 | 2012-09-11 | Johnson Lanny L | Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions |
US20130203688A1 (en) * | 2010-08-20 | 2013-08-08 | Fédération Des Producteurs Acéri-Coles Du Québec | Sugar plant derived by-products and methods of production thereof |
WO2014032100A1 (en) | 2012-08-28 | 2014-03-06 | Phytolin Pty Ltd | Extraction method |
US8673862B1 (en) | 2012-09-06 | 2014-03-18 | Food Industry Research And Development Institute | Peptides and use thereof in the inhibition of angiotensin converting enzyme |
US9968623B2 (en) | 2013-08-29 | 2018-05-15 | Lanny Leo Johnson | Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent |
JP2017176907A (ja) * | 2016-03-28 | 2017-10-05 | 株式会社日本カプセルプロダクツ | マイクロカプセルの製造方法及びこの製造方法で製造されたマイクロカプセル |
WO2023277820A2 (en) * | 2021-06-30 | 2023-01-05 | Nutrition Science Design Pte. Ltd | Methods of feeding polyphenols to animals |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2362211C3 (de) * | 1973-12-14 | 1978-05-11 | Sueddeutsche Zucker Ag, 6800 Mannheim | Verfahren zur Aufarbeitung von Melassen |
CH622004A5 (zh) * | 1975-04-10 | 1981-03-13 | Pfeifer & Langen | |
US4101338A (en) * | 1975-06-02 | 1978-07-18 | Sucrest Corporation | Process for recovering useful products from carbohydrate-containing materials |
US4116712A (en) * | 1977-09-06 | 1978-09-26 | Othmer Donald F | Solvent refining of sugar |
US4359430A (en) * | 1980-02-29 | 1982-11-16 | Suomen Sokeri Osakeyhtio | Betaine recovery process |
US4333770A (en) * | 1980-09-08 | 1982-06-08 | Uop Inc. | Extraction of sucrose from molasses |
FR2490676B1 (fr) * | 1980-09-19 | 1985-07-19 | Rhone Poulenc Spec Chim | Procede d'epuration des jus de canne a sucre |
US4404037A (en) * | 1982-08-12 | 1983-09-13 | Uop Inc. | Sucrose extraction from aqueous solutions featuring simulated moving bed |
US4523999A (en) * | 1983-12-16 | 1985-06-18 | Ajinomoto Co., Inc. | Ultrafiltration method |
JPS6169727A (ja) | 1984-09-14 | 1986-04-10 | Osaka Chem Lab | 蔗糖等糖類吸収抑制剤及び蔗糖糖類吸収抑制剤を含む食品 |
JPS61265068A (ja) | 1985-05-20 | 1986-11-22 | Osaka Chem Lab | 抗肥満食品 |
JPS61268200A (ja) | 1985-05-24 | 1986-11-27 | オルガノ株式会社 | 非糖分と糖分の分離方法 |
JPS62126951A (ja) | 1985-11-28 | 1987-06-09 | Nippon Beet Sugar Mfg Co Ltd | ビフイズス菌増殖糖質源を含有する甘味料の製造方法 |
JP2672138B2 (ja) * | 1987-08-21 | 1997-11-05 | フレクショネイテッド ケイン テクノロジー リミテッド | サトウキビ柔組織細胞壁を含有する低コレステロール食物 |
JPH0767398B2 (ja) | 1988-01-22 | 1995-07-26 | 三菱化成エンジニアリング株式会社 | 甜菜糖液を処理する方法 |
FI86416C (fi) * | 1988-06-09 | 1992-08-25 | Suomen Sokeri Oy | Foerfarande foer tillvaratagande av betain ur melass. |
JP2816725B2 (ja) | 1989-10-31 | 1998-10-27 | 万田発酵株式会社 | 糖類吸収抑制剤 |
EP0481603A1 (en) | 1990-10-15 | 1992-04-22 | The Dow Chemical Company | Separation of weak organic acids from liquid mixtures |
US5096594A (en) * | 1990-12-20 | 1992-03-17 | Israel Rabinowitz | Chromatographic method of purifying cyclitols |
JPH04320691A (ja) | 1991-04-22 | 1992-11-11 | Sumitomo Chem Co Ltd | 発酵有機酸の精製方法 |
US5382294A (en) * | 1991-08-26 | 1995-01-17 | Rimedio; Nicholas T. | Chromatographic separation of organic non-sugars, colloidal matterials and inorganic-organic complexes from juices, liquors, syrups and/or molasses |
JPH074277B2 (ja) | 1991-09-10 | 1995-01-25 | 北海道糖業株式会社 | 甘味料の製造方法 |
DE4231149C1 (de) * | 1992-09-17 | 1993-12-16 | Amino Gmbh | Verfahren zur Weiterverarbeitung von technischen Restabläufen der melasseverarbeitenden Industrie |
WO1994012057A1 (en) | 1992-11-25 | 1994-06-09 | Fujisawa Pharmaceutical Co., Ltd. | Diet sweetener |
FI96225C (fi) * | 1993-01-26 | 1996-05-27 | Cultor Oy | Menetelmä melassin fraktioimiseksi |
US5556546A (en) * | 1993-12-27 | 1996-09-17 | Mitsubishi Kasei Engineering Company | Method of separation into three components using a simulated moving bed |
RU2048847C1 (ru) | 1994-08-18 | 1995-11-27 | Татьяна Евгеньевна Митченко | Ионообменный способ комплексной переработки мелассы |
US5795398A (en) * | 1994-09-30 | 1998-08-18 | Cultor Ltd. | Fractionation method of sucrose-containing solutions |
US5482631A (en) * | 1994-10-06 | 1996-01-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Separation of inositols from sugars and sugar alcohols |
JPH0925290A (ja) | 1995-07-13 | 1997-01-28 | Tokiwa Kanpo Seiyaku:Kk | テンサイに含まれる新規化合物、医薬組成物および機能性食品 |
US6261565B1 (en) | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
IL119924A0 (en) * | 1996-12-27 | 1997-03-18 | Tate & Lyle Plc | A process for treating a sucrose syrup |
AUPO821397A0 (en) * | 1997-07-24 | 1997-08-14 | Commonwealth Scientific And Industrial Research Organisation | Process for the purification of nutrients from food process streams |
JP3383193B2 (ja) | 1997-08-29 | 2003-03-04 | 日本甜菜製糖株式会社 | 液体甘味料及びその製造方法 |
JP3539470B2 (ja) * | 1997-12-25 | 2004-07-07 | オルガノ株式会社 | ベタインの回収方法 |
MY134878A (en) * | 1998-09-24 | 2007-12-31 | Palm Oil Res And Dev Board | Treatment of liquors derived from oil-bearing fruit. |
IL127371A (en) * | 1998-12-02 | 2004-08-31 | Adumin Chemicals Ltd | Method for selectively obtaining antioxidant rich extracts from citrus fruits |
ES2303509T3 (es) * | 1999-07-02 | 2008-08-16 | Meiji Seika Kaisha, Ltd. | Composiciones para alimentos, proceso para su produccion y alimentos y bebidas funcionales que las contienen. |
DE60031921T2 (de) * | 1999-08-16 | 2007-09-20 | Dsm Ip Assets B.V. | Verfahren zu Herstellung von Epigallocatechin Gallate |
US6406548B1 (en) * | 2000-07-18 | 2002-06-18 | Tate & Lyle Industries, Limited | Sugar cane membrane filtration process |
US6406547B1 (en) * | 2000-07-18 | 2002-06-18 | Tate & Lyle Industries, Limited | Sugar beet membrane filtration process |
FI113453B (fi) * | 1999-09-17 | 2004-04-30 | Sohkar Oy | Kasvimateriaalin kromatografinen fraktiointi |
JP4678904B2 (ja) | 1999-11-02 | 2011-04-27 | アサヒビール株式会社 | ホップより得られる体重増加抑制物質 |
JP4358957B2 (ja) * | 2000-01-21 | 2009-11-04 | 三井製糖株式会社 | フリーラジカル又は活性酸素を消去もしくは低減する剤 |
AU2001241078B2 (en) * | 2000-03-10 | 2006-02-09 | Kabushiki Kaisha Yakult Honsha | Alpha-amylase activity inhibitors |
US6774111B1 (en) * | 2000-03-14 | 2004-08-10 | Abbott Laboratories | Carbohydrate system and a method for providing nutrition to a diabetic |
KR100350576B1 (ko) | 2000-04-14 | 2002-08-30 | 박 군 | 의료용 가온 장치 및 가온 제어방법 |
JP4737796B2 (ja) * | 2000-04-21 | 2011-08-03 | 三井製糖株式会社 | 肝機能増強剤 |
JP2002020306A (ja) | 2000-07-03 | 2002-01-23 | Chisso Corp | ラジカル消去物質およびそれを用いたラジカル消去剤 |
DE60135760D1 (de) * | 2000-08-01 | 2008-10-23 | Oryza Oil & Fat Chem | Nachtkerzensamenextrakte als inhibitoren der zuckerabsorption und deren herstellungsprozess |
EP1254209B1 (en) * | 2000-08-17 | 2006-03-15 | Sabinsa Corporation | Composition comprising hydroxycitric acid and garcinol for weight-loss |
AUPQ987400A0 (en) * | 2000-09-04 | 2000-09-28 | Food Ingredients Technologies Intangibles (Bermuda) Limited | Process for selectively extracting bioactive components |
FI20002150A (fi) * | 2000-09-29 | 2002-03-30 | Finnfeeds Finland Oy | Menetelmä tuotteiden talteenottamiseksi prosessiliuoksista |
FI20002149A (fi) * | 2000-09-29 | 2002-03-30 | Xyrofin Oy | Sakkaridien puhdistaminen kromatografisella erotuksella |
JP3793779B2 (ja) * | 2000-11-27 | 2006-07-05 | 沖縄県 | サトウキビポリフェノール含有物の製造方法 |
ATE544874T1 (de) * | 2000-12-28 | 2012-02-15 | Danisco | Trennverfahren |
CA2454636A1 (en) * | 2001-07-24 | 2003-02-06 | Cargill, Incorporated | Process for isolating phenolic compounds |
JP5002097B2 (ja) * | 2001-08-28 | 2012-08-15 | 独立行政法人農業・食品産業技術総合研究機構 | コクシジウムによって引き起こされるヒトまたは動物の病気に対する予防治療剤及びコクシジウムの軽感染に対するヒトまたは動物の免疫のためのアジュバント剤 |
US6638542B2 (en) * | 2001-09-20 | 2003-10-28 | Nutricia N.V. | Reducing appetite in mammals by administering procyanidin and hydroxycitric acid |
US6869625B2 (en) * | 2001-10-09 | 2005-03-22 | Council Of Scientific And Industrial Research | Method of treating diabetes using plant argyrolobium roseum extract, and a process for the isolation of extract from the said plant |
JP4199448B2 (ja) * | 2001-10-30 | 2008-12-17 | 琉球セメント株式会社 | サトウキビポリフェノール含有物を有効成分とする医薬剤並びにその用途 |
US6899892B2 (en) * | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
US20030165574A1 (en) * | 2002-03-01 | 2003-09-04 | Ward Loren Spencer | Compositions and methods for treatment of body weight conditions |
GB0205182D0 (en) * | 2002-03-06 | 2002-04-17 | Molecularnature Ltd | Process for extracting polar phytochemicals |
GB0205186D0 (en) * | 2002-03-06 | 2002-04-17 | Molecularnature Ltd | Method for monitoring the quality of a herbal medicine |
US7524526B2 (en) * | 2002-04-10 | 2009-04-28 | Archer-Daniels-Midland Company | Process for producing high purity isoflavones |
US20030198694A1 (en) * | 2002-04-22 | 2003-10-23 | Chou Chung Chi | Preparation antioxidants enriched functional food products from sugar cane and beet |
WO2003092599A2 (en) | 2002-04-30 | 2003-11-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
US7074440B2 (en) * | 2002-05-01 | 2006-07-11 | Rulin Xiu | Compositions and methods for body weight loss |
FI20021251A0 (fi) * | 2002-06-26 | 2002-06-26 | Finnfeeds Finland Oy | Menetelmä betaiinin talteenottamiseksi |
JP3644938B2 (ja) * | 2002-08-01 | 2005-05-11 | 株式会社東洋新薬 | 健康食品 |
US8129350B2 (en) * | 2002-08-07 | 2012-03-06 | Queen Bioactives Pty Ltd | Method of lowering Glycaemic Index of foods |
JP2004075612A (ja) * | 2002-08-19 | 2004-03-11 | National Agriculture & Bio-Oriented Research Organization | 免疫機能増強剤 |
US20040131749A1 (en) * | 2002-08-29 | 2004-07-08 | Archer-Daniels-Midland Company | Phytochemicals from edible bean process streams |
CN1262201C (zh) | 2002-09-25 | 2006-07-05 | 周重吉 | 由甘蔗及甜菜制备强化抗氧化基之机能性食品之方法 |
PL377399A1 (pl) * | 2002-11-06 | 2006-02-06 | Danisco Sugar Oy | Dodatek jadalny polepszający smakowość, sposób jego wytwarzania i jego zastosowanie |
US20040097429A1 (en) | 2002-11-18 | 2004-05-20 | Nieuwenhuizen Arie Gijsbert | Method for the reduction of the mammalian appetite |
US20060121158A1 (en) * | 2003-06-04 | 2006-06-08 | Mario Ferruzzi | Weight management beverage |
AU2003903058A0 (en) * | 2003-06-18 | 2003-07-03 | Phytopharm Australia Ltd | A process and apparatus for the modification of plant extracts |
US20050008712A1 (en) * | 2003-07-08 | 2005-01-13 | Debasis Bagchi | Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight |
JP4181067B2 (ja) | 2003-09-18 | 2008-11-12 | Dxアンテナ株式会社 | 多周波数帯アンテナ |
JPWO2005074962A1 (ja) * | 2004-02-10 | 2007-09-13 | アサヒビール株式会社 | 筋張力増強剤 |
KR101191070B1 (ko) * | 2004-02-17 | 2012-10-15 | 산토리 홀딩스 가부시키가이샤 | 고분자 폴리페놀 획분을 함유하는 리파아제 활성 저해제,차 엑기스, 및 그 제조 방법 |
WO2005089066A2 (en) * | 2004-03-23 | 2005-09-29 | Rimonest Ltd. | Pharmaceutical compositions, methods of formulation thereof and methods of use thereof |
JP4182524B2 (ja) | 2004-03-26 | 2008-11-19 | 北海道糖業株式会社 | ビート含蜜糖の製造方法 |
WO2006049258A1 (ja) * | 2004-11-04 | 2006-05-11 | University Of Tsukuba | 発酵茶から抽出された高分子ポリフェノール、ミトコンドリア病治療剤、糖尿病予防・治療剤、並びに飲食物 |
JP3671190B1 (ja) | 2004-11-09 | 2005-07-13 | 松浦薬業株式会社 | 蓮植物体から得られた抽出物、該抽出物の製造方法及び肥満防止剤 |
CN1685929A (zh) | 2005-05-08 | 2005-10-26 | 颜怀玮 | 正常能量代谢复合必需维生素微量元素及营养型白糖产品和制造方法 |
JP5340520B2 (ja) | 2005-05-20 | 2013-11-13 | ポッカサッポロフード&ビバレッジ株式会社 | 体重増加抑制剤 |
JP2007043940A (ja) | 2005-08-09 | 2007-02-22 | Hokkaido Univ | イノシトール回収方法 |
JP5563181B2 (ja) | 2005-09-01 | 2014-07-30 | ポッカサッポロフード&ビバレッジ株式会社 | インスリン抵抗性改善剤及び血糖値低下剤 |
US8864995B2 (en) * | 2006-01-10 | 2014-10-21 | Dupont Nutrition Biosciences Aps | Method for separating betaine |
JP2008044872A (ja) | 2006-08-11 | 2008-02-28 | Nippon Supplement Kk | イソラリシレシノールを含有する健康食品、血中コレステロール降下剤および体脂肪低下剤 |
JP2008222656A (ja) | 2007-03-14 | 2008-09-25 | Orient Herb Kk | 肥満改善および予防用組成物ならびに健康食品 |
GB0719545D0 (en) * | 2007-10-08 | 2007-11-14 | Barry Callebaut Ag | Novel use of cocoa extract |
GB0719542D0 (en) * | 2007-10-08 | 2007-11-14 | Barry Callebaut Ag | Use of cocoa extract |
US20100166851A1 (en) * | 2007-05-04 | 2010-07-01 | Nutraceutic Et Business Consulting | Composition having lipolytic activity, production method thereof and use of the composition |
US20080286254A1 (en) * | 2007-05-17 | 2008-11-20 | Kaneka Corporation | Composition comprising licorice polyphenol |
KR100954217B1 (ko) | 2007-12-14 | 2010-04-21 | (주)세전 | 유기산을 이용한 l-아라비노스 함유 추출액의 제조 방법 |
FR2929852B1 (fr) | 2008-04-09 | 2010-08-13 | Alvend | Procede de preparation d'extrait vegetal riche en polyphenols, extrait obtenu a partir du procede, compositions renfermant ledit extrait et installation pour la mise en oeuvre du procede |
US8288364B2 (en) * | 2008-05-09 | 2012-10-16 | Indus Biotech Private Limited | Botanically derived composition and a process thereof |
JP2009298769A (ja) | 2008-05-14 | 2009-12-24 | Asahi Breweries Ltd | 脂肪蓄積抑制用組成物 |
CN101317850B (zh) | 2008-05-20 | 2012-07-04 | 淮北中润生物能源技术开发有限公司 | 蔗糖吸收抑制剂 |
KR100894911B1 (ko) | 2008-09-12 | 2009-04-30 | (주)세전 | Sbp 추출물을 함유하는 당 함유 식품 조성물 |
EP2349305A4 (en) * | 2008-11-04 | 2012-08-22 | Metaproteomics Llc | PHYTOCHEMICAL COMPOSITIONS AND METHOD FOR AMP-KINASE ACTIVATION |
-
2006
- 2006-06-05 WO PCT/AU2006/000769 patent/WO2006128259A1/en active Application Filing
- 2006-06-05 JP JP2008513874A patent/JP5775656B2/ja not_active Expired - Fee Related
- 2006-06-05 EP EP06741186A patent/EP1885453A4/en not_active Withdrawn
- 2006-06-05 ES ES11177041.8T patent/ES2457595T3/es active Active
- 2006-06-05 CA CA2608865A patent/CA2608865C/en not_active Expired - Fee Related
- 2006-06-05 MX MX2007014586A patent/MX2007014586A/es active IP Right Grant
- 2006-06-05 CN CN200680019626.0A patent/CN101203270B/zh active Active
- 2006-06-05 BR BRPI0613305-3A patent/BRPI0613305B1/pt not_active IP Right Cessation
- 2006-06-05 AU AU2006254652A patent/AU2006254652B2/en active Active
- 2006-06-05 US US11/915,838 patent/US8021697B2/en not_active Expired - Fee Related
- 2006-06-05 EP EP11177041.8A patent/EP2450084B1/en active Active
-
2011
- 2011-07-26 US US13/190,608 patent/US8697145B2/en not_active Expired - Fee Related
-
2012
- 2012-11-08 HK HK12111304.4A patent/HK1170971A1/xx not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103561585A (zh) * | 2011-02-08 | 2014-02-05 | 视界科技有限公司 | 糖提取物 |
CN103561585B (zh) * | 2011-02-08 | 2016-05-25 | 产品制造者(澳大利亚)有限公司 | 糖提取物 |
CN105722520A (zh) * | 2013-08-16 | 2016-06-29 | 产品制造商(澳大利亚)有限公司 | 甘蔗衍生提取物及治疗方法 |
CN107922458A (zh) * | 2015-07-01 | 2018-04-17 | 三得利控股株式会社 | 含有氨基酸及环状二肽的组合物 |
CN107922458B (zh) * | 2015-07-01 | 2022-01-21 | 三得利控股株式会社 | 含有氨基酸及环状二肽的组合物 |
CN112384074A (zh) * | 2018-05-11 | 2021-02-19 | 产品制造商(澳大利亚)有限公司 | 用于动物饲料的甘蔗提取物 |
Also Published As
Publication number | Publication date |
---|---|
EP2450084B1 (en) | 2014-02-19 |
EP1885453A1 (en) | 2008-02-13 |
WO2006128259A1 (en) | 2006-12-07 |
AU2006254652B2 (en) | 2011-04-21 |
US8021697B2 (en) | 2011-09-20 |
CA2608865C (en) | 2015-08-25 |
EP1885453A4 (en) | 2011-06-29 |
MX2007014586A (es) | 2008-02-05 |
US8697145B2 (en) | 2014-04-15 |
CN101203270B (zh) | 2014-07-02 |
BRPI0613305A2 (pt) | 2010-12-28 |
BRPI0613305B1 (pt) | 2020-09-29 |
US20080200559A1 (en) | 2008-08-21 |
EP2450084A1 (en) | 2012-05-09 |
JP2008542307A (ja) | 2008-11-27 |
AU2006254652A1 (en) | 2006-12-07 |
US20110280974A1 (en) | 2011-11-17 |
HK1170971A1 (en) | 2013-03-15 |
CA2608865A1 (en) | 2006-12-07 |
JP5775656B2 (ja) | 2015-09-09 |
ES2457595T3 (es) | 2014-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101203270B (zh) | 具有体重再分配性能的物质 | |
Yuan et al. | Hypoglycemic and anti-inflammatory effects of seabuckthorn seed protein in diabetic ICR mice | |
KR101144059B1 (ko) | 석류 추출물 및 홍삼 추출물을 포함하는 당뇨병 또는비만의 예방 또는 치료용 조성물 | |
JP2008174539A (ja) | 紫色の馬鈴薯を使用した肥満患者用の健康機能食品 | |
Ning et al. | Recent advances in the managements of type 2 diabetes mellitus and natural hypoglycemic substances | |
SADIQ | SEX REVERSAL OF NILE TILAPIA Oreochromis niloticus (LINNEAUS, 1758) USING DIFFERENTLY PROCESSED Tribulus terrestris L. EXTRACTS | |
CN106456693A (zh) | 糖尿病预防或改善剂 | |
CN100444746C (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
KR102172369B1 (ko) | 보리 새싹 급여를 통한 기능성 계란 생산 방법 및 상기 방법에 의하여 생산된 기능성 계란 | |
KR20160059137A (ko) | 유산균 및 천연효소를 이용한 발효삼채 제조 및 숙취해소용 혼합음료 제조방법 | |
KR20150083622A (ko) | 오갈피나무와 뽕나무를 이용한 항비만 조성물 | |
CN109481540A (zh) | 用于防治动物乳房炎的组合物及其制备方法和应用 | |
CN102687855A (zh) | 生产含草药的膳食的方法 | |
KR102084001B1 (ko) | 황태 껍질 발효물을 포함하는 비만 개선, 예방 및 치료용 조성물 | |
CN108391815A (zh) | 一种润肠减肥组合物及制备方法 | |
KR102571313B1 (ko) | 삼백초추출물과 녹차추출물이 포함된 비만 예방 및 개선용 식품조성물 및 그 제조방법 | |
CN115400189B (zh) | 糖脂同调的中药组合物、提取物、制备方法及应用和制剂 | |
KR102380291B1 (ko) | 풀무치 추출물을 포함하는 비만 예방 또는 치료용 조성물 | |
WO2008041049A1 (en) | Cinnamomum zeylanicum plant extracts for the treatment of diabetes and the extraction process thereof | |
Lieshchova et al. | Diversity | |
AU2011204849A1 (en) | Substances having body mass redistribution properties | |
Lieshchova et al. | The effect on the organism of rats of adding Helichrysum arenarium inflorescences to a hypercaloric diet, high in sugar and fat | |
SA Ahmed | Effect of White, Black Rice and their Mixtures on Induced-Hypercholesterolemia in Rats | |
CN110464007A (zh) | 具有利肾、抗衰老功能的保健饮料配方及其制备方法 | |
Foomaneechot | Physicochemical properties and biological activities of Thai originated honeys |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160115 Address after: Vitoria, Australia Patentee after: THE PRODUCT MAKERS (AUSTRALIA) Pty Ltd. Address before: Vitoria, Australia Patentee before: Horizon Science Pty Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20231207 Address after: Singapore, Singapore City Patentee after: Poly Gain Private Ltd. Address before: Vitoria, Australia Patentee before: THE PRODUCT MAKERS (AUSTRALIA) Pty Ltd. |
|
TR01 | Transfer of patent right |